CODX Stock Overview
Operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Co-Diagnostics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.36 |
| 52 Week High | US$2.23 |
| 52 Week Low | US$0.28 |
| Beta | 1.21 |
| 1 Month Change | -22.25% |
| 3 Month Change | -55.22% |
| 1 Year Change | -68.42% |
| 3 Year Change | -92.00% |
| 5 Year Change | -96.83% |
| Change since IPO | -93.80% |
Recent News & Updates
Recent updates
Is Co-Diagnostics (NASDAQ:CODX) In A Good Position To Deliver On Growth Plans?
Feb 25
Here's Why We're Watching Co-Diagnostics' (NASDAQ:CODX) Cash Burn Situation
Jun 14One Co-Diagnostics, Inc. (NASDAQ:CODX) Analyst Just Slashed Their Estimates By A Consequential 14%
May 18A Look At The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)
Apr 14Co-Diagnostics: Hold Thesis Remains Well Intact
Sep 07Co-Diagnostics stock sinks ~37% after hours on Q2 results miss, hurt by lower volumes
Aug 11Co-Diagnostics spikes on shipments of monkeypox test
Jul 11Estimating The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)
Jul 06Co-Diagnostics: Well Priced, Long-Term Value Remains Too Distant
Jun 21Co-Diagnostics: Where's Eikon?
Apr 03Co-Diagnostics, Inc. (NASDAQ:CODX) Shares Could Be 29% Below Their Intrinsic Value Estimate
Mar 28Co-Diagnostics: Swinging For The Fences
Jan 24Does Co-Diagnostics (NASDAQ:CODX) Deserve A Spot On Your Watchlist?
Dec 28Why Co-Diagnostics Is A Solid Covid-19 Play
Aug 19Shareholder Returns
| CODX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 3.6% | 1.8% | 2.3% |
| 1Y | -68.4% | 3.4% | 5.9% |
Return vs Industry: CODX underperformed the US Medical Equipment industry which returned 3.4% over the past year.
Return vs Market: CODX underperformed the US Market which returned 5.9% over the past year.
Price Volatility
| CODX volatility | |
|---|---|
| CODX Average Weekly Movement | 12.4% |
| Medical Equipment Industry Average Movement | 9.2% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: CODX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CODX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 132 | Dwight Egan | co-dx.com |
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus.
Co-Diagnostics, Inc. Fundamentals Summary
| CODX fundamental statistics | |
|---|---|
| Market cap | US$11.88m |
| Earnings (TTM) | -US$37.64m |
| Revenue (TTM) | US$3.92m |
3.1x
P/S Ratio-0.3x
P/E RatioIs CODX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CODX income statement (TTM) | |
|---|---|
| Revenue | US$3.92m |
| Cost of Revenue | US$999.12k |
| Gross Profit | US$2.92m |
| Other Expenses | US$40.56m |
| Earnings | -US$37.64m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.12 |
| Gross Margin | 74.48% |
| Net Profit Margin | -961.37% |
| Debt/Equity Ratio | 0% |
How did CODX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/24 22:14 |
| End of Day Share Price | 2025/04/24 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Co-Diagnostics, Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yi Chen | H.C. Wainwright & Co. |
| James Sidoti | Sidoti & Company, LLC |